drug · small molecule
patient view →risperidone ER
Phase 3updated 2mo agoby Lyndra Therapeutics Inc.🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 24 investigational indications.
targets
5-hydroxytryptamine receptor 2A5-hydroxytryptamine receptor 2CD(2) dopamine receptor
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that